Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Dow
Johnson and Johnson
AstraZeneca
Colorcon

Last Updated: November 26, 2022

Deferiprone - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for deferiprone and what is the scope of patent protection?

Deferiprone is the generic ingredient in two branded drugs marketed by Chiesi, Hikma, and Taro Pharm Inds Ltd, and is included in five NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Deferiprone has forty patent family members in twenty-seven countries.

There are four drug master file entries for deferiprone. Four suppliers are listed for this compound.

Drug Prices for deferiprone

See drug prices for deferiprone

Recent Clinical Trials for deferiprone

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University Hospital, BordeauxPhase 2
David HasanPhase 2
First Affiliated Hospital of Fujian Medical UniversityEarly Phase 1

See all deferiprone clinical trials

Pharmacology for deferiprone
Drug Class Iron Chelator
Mechanism of ActionIron Chelating Activity
Paragraph IV (Patent) Challenges for DEFERIPRONE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FERRIPROX Tablets deferiprone 500 mg 021825 1 2016-01-29

US Patents and Regulatory Information for deferiprone

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hikma DEFERIPRONE deferiprone TABLET;ORAL 213239-001 Mar 29, 2021 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-002 Apr 20, 2018 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-001 Sep 9, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Chiesi FERRIPROX deferiprone TABLET;ORAL 212269-001 May 19, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Chiesi FERRIPROX deferiprone TABLET;ORAL 212269-001 May 19, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Chiesi FERRIPROX deferiprone TABLET;ORAL 021825-002 Jul 25, 2019 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for deferiprone

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-002 Apr 20, 2018 See Plans and Pricing See Plans and Pricing
Chiesi FERRIPROX deferiprone TABLET;ORAL 021825-002 Jul 25, 2019 See Plans and Pricing See Plans and Pricing
Chiesi FERRIPROX deferiprone TABLET;ORAL 021825-001 Oct 14, 2011 See Plans and Pricing See Plans and Pricing
Chiesi FERRIPROX deferiprone TABLET;ORAL 212269-001 May 19, 2020 See Plans and Pricing See Plans and Pricing
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-001 Sep 9, 2015 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for deferiprone

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Chiesi Farmaceutici S.p.A. Ferriprox deferiprone EMEA/H/C/000236
Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.
Authorised no no no 1999-08-25
Lipomed GmbH Deferiprone Lipomed deferiprone EMEA/H/C/004710
Deferiprone Lipomed monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Deferiprone Lipomed in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction.
Authorised yes no no 2018-09-19
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for deferiprone

Country Patent Number Title Estimated Expiration
South Africa 201008374 LIQUID FORMULATION FOR DEFERIPRONE WITH PALATABLE TASTE See Plans and Pricing
Eurasian Patent Organization 201071235 ЖИДКАЯ КОМПОЗИЦИЯ ДЛЯ ДЕФЕРИПРОНА С ПРИЯТНЫМ ВКУСОМ See Plans and Pricing
World Intellectual Property Organization (WIPO) 2019082128 See Plans and Pricing
China 114533689 延迟释放去铁酮片剂及其使用方法 (Delayed release deferiprone tablets and methods of use thereof) See Plans and Pricing
World Intellectual Property Organization (WIPO) 2009129592 See Plans and Pricing
South Korea 101490721 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Express Scripts
Mallinckrodt
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.